Valvular heart disease in pergolide-treated Parkinson's disease

Can J Neurol Sci. 2006 Feb;33(1):111-3. doi: 10.1017/s0317167100004819.

Abstract

Background: A 61-year-old woman with Parkinson's disease, receiving pergolide 1.75 mg four times daily, was admitted with progressive dyspnea.

Methods: Investigations revealed mitral and aortic regurgitation. She underwent surgical mitral replacement and aortic repair, but had a post-operative course characterized by repeated bouts of congestive heart failure.

Results: Severe tricuspid valve (TV) regurgitation developed within one month after the TV was reported on echocardiography to be relatively normal. Subsequent discontinuation of pergolide was associated with symptomatic improvement.

Conclusions: This case illustrates the severity and rapidity with which cardiac valvular abnormalities can develop in patients receiving pergolide.

MeSH terms

  • Aged
  • Antiparkinson Agents / therapeutic use*
  • Female
  • Heart Valve Diseases / chemically induced*
  • Heart Valve Diseases / pathology
  • Humans
  • Parkinson Disease / drug therapy*
  • Pergolide / therapeutic use*

Substances

  • Antiparkinson Agents
  • Pergolide